This is a routine CFO appointment with no immediate trading implications. Monitor for any future strategic or financial updates from the new CFO, but no near-term catalyst is expected from this filing.
Price Chart
Executive Summary
Kura Oncology appointed Jennifer Fulk as CFO, replacing Troy E. Wilson and Thomas Doyle in those roles, effective September 8, 2026. This is a routine executive appointment with standard compensation terms, including a $550,000 base salary, an option for 450,000 shares, and a performance-based RSU award. No red flags such as unexpected departures or resignations are present, making this a neutral event.
Key Facts
- Jennifer Fulk appointed CFO, principal financial officer, and principal accounting officer effective September 8, 2026.
- Annual base salary of $550,000, with eligibility for an annual discretionary bonus of up to 45% of base salary.
- Received an option to purchase 450,000 shares vesting over 4 years and a performance-based RSU award covering 173,438 shares.
- No unexpected departures or resignations; the appointment is a standard executive change.
Financial Impact
Standard executive compensation package with $550,000 base salary and equity awards totaling 623,438 shares (450,000 options + 173,438 PSUs). No material financial impact.
Risk Factors
- No material risks identified from this routine executive change.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-384363 |
| Document: 0001193125-26-384363-index-headers.html | 0001193125-26-384363 |
| Document: 0001193125-26-384363-index.html | 0001193125-26-384363 |
| Document: 0001193125-26-384363.txt | 0001193125-26-384363 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $12.09 $11.37 | ▼ −6.00% | ▼ −5.66% | $10.65 (−11.91%) |
Sep 8, 2026 24d ago | 8-K | $12.52 $11.30 | ▼ −9.74% | ▼ −8.63% | $10.65 (−14.94%) |
Aug 24, 2026 5w ago | Insider Cluster | $12.40 $12.65 | ▲ +2.02% | ▲ +1.55% | $10.65 (−14.11%) |
Aug 21, 2026 6w ago | Insider Cluster | $11.89 $12.66 | ▲ +6.48% | ▲ +6.00% | $10.65 (−10.43%) |
Aug 17, 2026 6w ago | Insider Buy | $12.33 $13.59 | ▲ +10.22% | ▲ +10.42% | $10.65 (−13.63%) |
Aug 12, 2026 7w ago | Press Release | $10.09 $11.71 | ▲ +16.06% | ▲ +18.02% | $10.65 (+5.55%) |
Aug 5, 2026 8w ago | Press Release | $9.20 $9.94 | ▲ +8.04% | ▲ +7.69% | $10.65 (+15.76%) |
Jul 29, 2026 9w ago | 8-K | $9.31 $9.28 | ▼ −0.32% | ▼ −3.94% | $10.65 (+14.39%) |
Jul 14, 2026 11w ago | Press Release | $11.24 $10.68 | ▼ −4.98% | ▼ −3.69% | $10.65 (−5.25%) |
Jun 3, 2026 17w ago | Press Release | $8.66 $8.68 | ▲ +0.29% | ▲ +4.11% | $10.65 (+23.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access